Postpartum Preeclampsia Early Detection and Treatment in Nepal: A Pilot Study
Official title: Postpartum Preeclampsia Early Detection and Treatment: Using Biomarkers to Implement Risk-stratified Intervention (Nepal Pilot Randomized Controlled Trial)
Run by Medical College of Wisconsin · NCT07185204 · Data updated 2026-11-12
This pilot study tests whether using sFlt-1/PlGF biomarker testing before delivery can predict postpartum preeclampsia and whether an early monitoring and treatment bundle helps high-risk, postpartum patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Medical College of Wisconsin Academic / other |
| Locations | 2 sites (Milwaukee, Wisconsin and 1 other locations) |
| Status | Recruiting |
| Started | March 3, 2026 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | July 20, 2026 |
| Trial ID | NCT07185204 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant adults at or beyond 36 weeks gestation, at risk for preeclampsia, delivering at Dhulikhel Hospital or planning to do so, and able to use remote monitoring.
✕Probably not a fit
Patients not at high risk or who do not develop postpartum preeclampsia may not benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot randomized trial enrolls 60 normotensive pregnant patients at risk for preeclampsia and uses pre-delivery sFlt-1/PlGF ratio testing to stratify risk. High-risk participants are randomized to receive an early detection and management bundle or routine postpartum care; low-risk participants receive routine care. The bundle includes remote blood pressure monitoring, education, and outpatient antihypertensive medication as needed. The primary outcome is feasibility of procedures (recruitment, retention, adherence, acceptability). Secondary outcomes assess the impact on hypertension requiring in-person care and related morbidity, with exploratory analysis of sFlt-1/PlGF’s predictive ability in at-risk, normotensive patients. Data are collected from both randomized groups and the lower-risk non-randomized group.
Why it matters
Potential benefit: If successful, the approach could enable earlier detection and management of postpartum preeclampsia, potentially reducing morbidity.
How similar studies have gone: This is a pilot study; prior data on sFlt-1/PlGF ratio use for postpartum risk stratification are limited in this specific setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
* Age ≥ 18 years
* Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
* At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
* 1 or more high risk factors:
* History of preeclampsia
* Type 1 or 2 diabetes
* Multifetal gestation?
* Renal disease
* Autoimmune disease
* 2 or more moderate risk factors:
* Nulliparity
* BMI \> 30
* First-degree relative with a history of preeclampsia
* African American race
* Low socioeconomic status
* Age \> 35 years
* History of low birthweight or small for gestational age
* Previous adverse pregnancy outcome
* Interpregnancy interval \> 10 years
Exclusion Criteria:
* Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
* Chronic hypertension, according to ACOG guidelines
* Known allergy or contraindication to nifedipine
* Inability or unwillingness to provide informed consent
* Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)
Where it's running
-
Dhulikhel Hospital
Dhulikhel, Nepal Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Active not recruiting
Study contacts
- Principal investigator: Anna Palatnik, MD — Medical College of Wisconsin
- Study coordinator: Alyssa Hernandez, DO
- Email: alyhernandez@mcw.edu
- Phone: 4148055285
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nifedipine and Enalapril vs Nifedipine and Labetalol for Postpartum Hypertension
This study tests whether adding enalapril to nifedipine better controls postpartum hypertension than adding labetalol.
-
Remote monitoring program for postpartum hypertension in Rhode Island
This study is testing a new remote monitoring program for postpartum hypertension to see if it helps new moms manage their blood pressure better than the usual self-check methods.
-
Comparing Labetalol and Nifedipine for Managing Postpartum Hypertension
This study is testing whether Labetalol or Nifedipine is better at managing high blood pressure after childbirth to help new moms avoid going back to the hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.